A Phase 2 interventional study of MF59C.1-adjuvanted subunit influenza vaccine and Sub unit, Inactivated, Influenza vaccine in Seasonal Influenza, Influenza and Influenza Due to Unspecified Influenza Virus, sponsored by Novartis Vaccines. Completed at 2 sites in Belgium. Open to participants aged 6 Months to 36 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-19.
Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 101 studies in Influenza, Human by Novartis — none open to participants now, none under way, none of them phase 3. Influenza, Human · Novartis.
Among the 101 studies in Influenza, Human by Novartis, this one is the 81st largest by enrollment of the 97 interventional ones that give a count, is one of 5 that started in 2011, is one of 42 in phase 2, and was the 77th registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →None of the 101 studies in Influenza, Human by Novartis is open now. The open studies under Influenza, Human, anywhere →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 6 Months to 36 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
101 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 48 · Phase 3 45 · Phase 4 5
First in 2004; this study’s year is marked. 5 started in 2011.
This study's enrollment of 84 is below the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 270 across the 97 interventional studies, 4,279 across the 4 observational. Of the 100 that completed or were terminated, 48 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Vaccines, one of the names counted as Novartis. Under that name alone:
Novartis Vaccines is the lead sponsor of 165 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 101 studies in Influenza, Human by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the immunogenicity, by means of cell mediated immunity (CMI) and hemagglutination inhibition (HI) assay, and also the safety of a MF59C.1-adjuvanted subunit influenza vaccine compared with a conventional subunit vaccine in previously unvaccinated children aged 6 to \<36 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: MF59C.1-adjuvanted subunit influenza vaccine
Biological: Sub unit, Inactivated, Influenza vaccine
2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
Cell Mediated Immune (CMI) Responses After In-vitro Restimulation Of Peripheral Blood Mononuclear Cells (PBMC) Following Vaccination.
The CMI responses were determined by intracellular staining/Fluorescence-Activated Cell Sorting(ICS/FACS) after in-vitro restimulation of PBMC with vaccine antigens on day 0 and day 50.
Time frame: Day 1, Day 50
Number of Subjects Reporting Unsolicited Adverse Events After Receiving Two Doses of aTIV and TIV
The number of subjects reporting unsolicited AEs between Day 1 and the study termination i.e., Day 50, after receiving two doses of aTIV and TIV. Data are reported based on the Safety Set.
Time frame: Day 1 to Day 50 post vaccination
Percentage of Subjects Achieving Seroconversion or Significant Increase in HI Titer
To evaluate the immune responses by seroconversion of aTIV or TIV according to CHMP criteria for seasonal influenza vaccines as determined by hemagglutination inhibition (HI) test on plasma from previously unvaccinated healthy children aged 6 to \< 36 months for all three strains. Criteron: The proportion of subjects achieving seroconversion or significant increase in HI titer should be \> 40%.
Time frame: Day 50
Geometric Mean Ratios (GMR)
To evaluate the immune responses by mean geometric increase (GMR) of aTIV or TIV according to CHMP criteria for seasonal influenza vaccines as determined by hemagglutination inhibition (HI) test on plasma from previously unvaccinated healthy children aged 6 to \< 36 months for all three strains. Criterion: Mean geometric increase (GMR) should be \> 2.5.
Time frame: Day 50/Day 1
Percentage of Subjects With HI Titers >1:40
To evaluate the immune responses by proportion of subjects with HI titers \>1:40 of aTIV or TIV according to CHMP criteria for seasonal influenza vaccines as determined by hemagglutination inhibition (HI) test on plasma from previously unvaccinated healthy children aged 6 to \< 36 months for all three strains. Criterion: The proportion of subjects with HI titers \>1:40 should be \> 70%
Time frame: Day 50
Subjects were recruited from two sites in Belgium.
| Milestone | aTIV Group | TIV Group |
|---|---|---|
| Started | 43 | 41 |
| Completed | 40 | 38 |
| Not completed | 3 | 3 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 3 |
| Withdrew: Inappropriate enrollment | 1 | 0 |
The CMI responses were determined by intracellular staining/Fluorescence-Activated Cell Sorting(ICS/FACS) after in-vitro restimulation of PBMC with vaccine antigens on day 0 and day 50.
| Cells per Million Total Cells | aTIV Group | TIV Group |
|---|---|---|
| Any Cytokine - A/H1N1, Day 1 | 631 (477 to 784) | 655 (503 to 806) |
| Any Cytokine - A/H1N1, Day 50 | 1560 (1244 to 1876) | 1137 (826 to 1449) |
| Any Cytokine - A/H3N2, Day 1 | 503 (346 to 660) | 462 (322 to 602) |
| Any Cytokine - A/H3N2, Day 50 | 1328 (1105 to 1550) | 671 (474 to 869) |
| Any Cytokine - B/Brisbane, (N=19, 24), Day 1 | 648 (452 to 844) | 753 (579 to 927) |
| Any Cytokine - B/Brisbane, Day 50 | 2369 (1940 to 2798) | 1062 (677 to 1446) |
| Any cytokine - B/Florida, Day 1 | 605 (215 to 996) | 749 (483 to 1015) |
| Any cytokine - B/Florida, Day 50 | 1607 (1113 to 2100) | 996 (662 to 1330) |
| Any Cytokine - SEB, Day 1 | 77048 (55913 to 98182) | 107200 (91682 to 122719) |
| Any Cytokine - SEB, Day 50 | 80400 (56864 to 103935) | 105013 (88270 to 121755) |
| Any cytokine -Tetanus toxoid, Day 1 | 1246 (639 to 1852) | 1368 (914 to 1822) |
| Any cytokine -Tetanus toxoid, Day 50 | 1162 (759 to 1565) | 1229 (928 to 1531) |
| IL-2- A/H1N1, Day 1 | 283 (207 to 359) | 240 (165 to 315) |
| IL-2- A/H1N1, Day 50 | 1141 (858 to 1423) | 642 (366 to 918) |
| IL-2 - A/H3N2, Day 1 | 212 (140 to 283) | 184 (121 to 248) |
| IL-2 - A/H3N2, Day 50 | 925 (723 to 1126) | 387 (208 to 566) |
| IL-2- B/Brisbane, Day 1 | 301 (183 to 419) | 330 (225 to 435) |
| IL-2- B/Brisbane, Day 50 | 1704 (1321 to 2087) | 610 (267 to 954) |
| IL-2 - B/Florida, Day 1 | 375 (119 to 632) | 275 (100 to 449) |
| IL-2 - B/Florida, Day 50 | 1094 (691 to 1497) | 541 (268 to 813) |
| IL-2 - SEB, Day 1 | 67524 (47735 to 87313) | 93312 (78781 to 107843) |
| IL-2 - SEB, Day 50 | 67357 (46682 to 88033) | 92489 (77768 to 107210) |
| IL-2 - Tetanus toxoid, Day 1 | 604 (309 to 899) | 672 (451 to 892) |
| IL-2 - Tetanus toxoid, Day 50 | 659 (291 to 1027) | 765 (489 to 1041) |
| IFN-γ - A/H1N1, Day 1 | 92 (49 to 135) | 116 (73 to 158) |
| IFN-γ - A/H1N1, Day 50 | 257 (163 to 350) | 248 (156 to 340) |
| IFN-γ - A/H3N2, Day 1 | 78 (44 to 112) | 78 (48 to 108) |
| IFN-γ - A/H3N2, Day 50 | 191 (113 to 268) | 130 (61 to 199) |
| IFN-γ -B/Brisbane, Day 1 | 83 (37 to 130) | 122 (81 to 163) |
| IFN-γ -B/Brisbane, Day 50 | 331 (201 to 462) | 106 (-12.1 to 224) |
| IFN-γ - B/Florida, Day 1 | 112 (46 to 179) | 94 (49 to 139) |
| IFN-γ - B/Florida, Day 50 | 193 (67 to 320) | 145 (59 to 230) |
| IFN-γ - SEB, Day 1 | 3615 (2110 to 5120) | 4780 (3675 to 5885) |
| IFN-γ - SEB, Day 50 | 3858 (2367 to 5349) | 4519 (3390 to 5649) |
| IFN-γ - Tetanus toxoid, Day 1 | 156 (64 to 248) | 148 (80 to 217) |
| IFN-γ - Tetanus toxoid, Day 50 | 74 (4 to 144) | 163 (10 to 215) |
| TNF-α- A/H1N1, Day 1 | 128 (87 to 170) | 133 (92 to 174) |
| TNF-α- A/H1N1, Day 50 | 495 (368 to 621) | 290 (165 to 415) |
| TNF-α - A/H3N2, Day 1 | 81 (56 to 106) | 69 (46 to 91) |
| TNF-α - A/H3N2, Day 50 | 447 (324 to 571) | 202 (93 to 311) |
| TNF-α - B/Brisbane, Day 1 | 116 (62 to 170) | 152 (104 to 200) |
| TNF-α - B/Brisbane, Day 50 | 921 (658 to 1184) | 251 (13 to 490) |
| TNF-α - B/Florida, Day 1 | 149 (50 to 249) | 171 (103 to 238) |
| TNF-α - B/Florida, Day 50 | 614 (372 to 857) | 244 (77 to 410) |
| TNF-α-SEB, Day 1 | 25467 (15528 to 35406) | 37856 (30559 to 45154) |
| TNF-α-SEB, Day 50 | 32510 (22453 to 42566) | 34805 (27557 to 42054) |
| TNF-α-Tetanus toxoid, Day 1 | 537 (278 to 795) | 541 (348 to 735) |
| TNF-α-Tetanus toxoid, Day 50 | 384 (156 to 612) | 644 (473 to 815) |
| IL-13 - A/H1N1, Day 1 | 232 (132 to 332) | 170 (71 to 268) |
| IL-13 - A/H1N1, Day 50 | 242 (105 to 378) | 347 (212 to 483) |
| IL-13 - A/H3N2, Day 1 | 250 (154 to 346) | 174 (89 to 259) |
| IL-13 - A/H3N2, Day 50 | 361 (229 to 494) | 231 (114 to 348) |
| IL-13 - B/Brisbane, Day 1 | 184 (59 to 308) | 168 (57 to 278) |
| IL-13 - B/Brisbane, Day 50 | 346 (228 to 463) | 221 (116 to 326) |
| IL-13 - B/Florida, Day 1 | 150 (-27.62 to 329) | 88 (-33.78 to 209) |
| IL-13 - B/Florida, Day 50 | 97 (18 to 175) | 93 (39 to 146) |
| IL-13 -SEB, Day 1 | 1017 (547 to 1487) | 950 (605 to 1295) |
| IL-13 -SEB, Day 50 | 772 (391 to 1153) | 993 (714 to 1272) |
| IL-13 -Tetanus toxoid, Day 1 | 166 (-0.845 to 333) | 222 (98 to 347) |
| IL-13 -Tetanus toxoid, Day 50 | 247 (-21.88 to 516) | 293 (94 to 491) |
The number of subjects reporting unsolicited AEs between Day 1 and the study termination i.e., Day 50, after receiving two doses of aTIV and TIV. Data are reported based on the Safety Set.
| Participants | aTIV Group | TIV Group |
|---|---|---|
| Any Adverse Event (AE) | 20 | 18 |
| At least possibly related AE | 1 | 3 |
| Any SAE | 0 | 2 |
| At least possibly related SAE | 0 | 0 |
| AE leading to discontinuation | 0 | 0 |
| Death | 0 | 0 |
To evaluate the immune responses by seroconversion of aTIV or TIV according to CHMP criteria for seasonal influenza vaccines as determined by hemagglutination inhibition (HI) test on plasma from previously unvaccinated healthy children aged 6 to \< 36 months for all three strains. Criteron: The proportion of subjects achieving seroconversion or significant increase in HI titer should be \> 40%.
| Percentage of participants | aTIV Group | TIV Group |
|---|---|---|
| A/H1N1/California | 100 (86 to 100) | 73 (54 to 88) |
| A/H3N2/Victoria | 100 (86 to 100) | 93 (78 to 99) |
| B/Brisbane | 100 (86 to 100) | 53 (34 to 72) |
To evaluate the immune responses by mean geometric increase (GMR) of aTIV or TIV according to CHMP criteria for seasonal influenza vaccines as determined by hemagglutination inhibition (HI) test on plasma from previously unvaccinated healthy children aged 6 to \< 36 months for all three strains. Criterion: Mean geometric increase (GMR) should be \> 2.5.
| titer ratio | aTIV Group | TIV Group |
|---|---|---|
| A/H1N1/California | 41 (23 to 74) | 9.99 (5.87 to 17) |
| A/H3N2/Victoria | 199 (130 to 303) | 35 (24 to 51) |
| B/Brisbane | 34 (22 to 52) | 5.63 (3.83 to 8.29) |
To evaluate the immune responses by proportion of subjects with HI titers \>1:40 of aTIV or TIV according to CHMP criteria for seasonal influenza vaccines as determined by hemagglutination inhibition (HI) test on plasma from previously unvaccinated healthy children aged 6 to \< 36 months for all three strains. Criterion: The proportion of subjects with HI titers \>1:40 should be \> 70%
| Percentage of participants | aTIV Group | TIV Group |
|---|---|---|
| A/H1N1/California | 100 (86 to 100) | 93 (78 to 99) |
| A/H3N2/Victoria | 100 (86 to 100) | 97 (83 to 100) |
| B/Brisbane | 100 (86 to 100) | 57 (37 to 75) |
Collected over All solicited AEs and unsolicited AEs were collected from Day 1 to Day 7; all unsolicited SAEs, medically attended AEs, AEs leading to withdrawal from the study were collected from Day 1 to Day 50.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| aTIV (6 to <36 Months) | — | 0/43 (0%) | 37/43 (86%) |
| TIV (6 to <36 Months) | — | 2/41 (4.9%) | 29/41 (70.7%) |
| Event | aTIV (6 to <36 Months) | TIV (6 to <36 Months) |
|---|---|---|
| VaricellaInfections and infestations | 0/43 | 1/41 |
| PneumoniaInfections and infestations | 0/43 | 1/41 |
| Event | aTIV (6 to <36 Months) | TIV (6 to <36 Months) |
|---|---|---|
| PyrexiaGeneral disorders | 19/43 | 15/41 |
| SomnolenceNervous system disorders | 11/43 | 12/41 |
| Eating DisorderPsychiatric disorders | 11/43 | 11/41 |
| DiarrhoeaGastrointestinal disorders | 11/43 | 11/41 |
| Injection site painGeneral disorders | 11/43 | 9/41 |
| IrratabilityPsychiatric disorders | 11/43 | 7/41 |
| Injection site erythemaGeneral disorders | 8/43 | 2/41 |
| CryingGeneral disorders | 6/43 | 7/41 |
| VomitingGastrointestinal disorders | 3/43 | 5/41 |
| NasopharyngitisGeneral disorders | 5/43 | 4/41 |
| Age, Continuous(years) | aTIV Group | TIV Group | Total |
|---|---|---|---|
| Mean | 20.2 ± 8.5 | 21.4 ± 9.7 | 20.8 ± 9.1 |
| Sex: Female, Male(Participants) | aTIV Group | TIV Group | Total |
|---|---|---|---|
| Female | 20 | 14 | 34 |
| Male | 23 | 27 | 50 |
The record gives a start of May 2011, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2021, 9 years 2 months after primary completion. A results delay was requested in Aug 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.